The Globe and Mail reports in its Monday edition that Adam Scioli is excited about GLP-1 medications, because he thinks this class of drugs is the next frontier of addictions treatment. The Globe's Alanna Smith writes that Dr. Scioli transformed care at Caron Treatment Centers as an addictions psychiatrist and chief medical officer. Caron is among the few rehab facilities globally that prescribe GLP-1s off-label for substance-use disorders. In 2024, Caron incorporated GLP-1s into its addiction medications, prescribing them to over 500 residential clients. Dr. Scioli noted that researchers cautioned them about acting prematurely, but they support their decision. "It's no doubt groundbreaking. It's no doubt transformative," Dr. Scioli said. GLP-1 medications Ozempic, Wegovy and Mounjaro (developed by Novo Nordisk and Eli Lilly) are only approved by the United States Federal Drug Administration and Health Canada for diabetes and chronic weight management. Early research, however, has shown that this class of drugs may help dampen drug cravings, similarly to how they quiet intrusive thoughts about food. Canadian researchers are part of a growing network of scientists who are putting such early findings to the test.